Page 1 | Search Results | Blood | American Society of Hematology

1-7 of 7

Sort by

Sort Order Select

Journal Articles

Ex Vivo Co-Culture of AML Blasts and Bone Marrow Mesenchymal Stromal Cells to Accurately Predict the Clinical Efficacy of Cytarabine-Daunorubicin Treatment

Sukhraj Pal Singh Dhami, MSc, BSc, Andrea Tirincsi, MSc, BSc, Denis V Baev, PhD, Janusz Krawczyk, MD, John Quinn, MD PhD, Eva Szegezdi, PhD

Blood (2018) 132 (Supplement 1): 2636.

https://doi.org/10.1182/blood-2018-99-118619

Published: 2018

Journal Articles

Cybord-Dara Is a Highly Effective Upfront Treatment for Newly Diagnosed Multiple Myeloma. Initial Efficacy Results of the 16-Bcni-001/Ctrial-IE (ICORG) 16-02 Study

Robert Henderson, MD, Mary R Cahill, MD, Philip Murphy, MD, Vitaliy Mykytiv, MD, John Quinn, MD PhD, Jessica Walsh, Elizabeth Lenihan, Tara Kenny, Andres Hernando, Grace Hirakata, Imelda Parker, Emma Kinsella, Grainne Gannon, Alessandro Natoni, PhD, Michael E O'Dwyer, MD

Blood (2018) 132 (Supplement 1): 3242.

https://doi.org/10.1182/blood-2018-99-112375

Published: 2018

Journal Articles

Acitretin Reduces L-Selectin Expression and Tumour Cell Homing in Chronic Lymphocytic Leukaemia (CLL)

Saad Ahmed, MBBS, Mattia Cremona, PhD, Sinead Toomey, PhD, Mark Catherwood, PhD, Stephen Bergin, BS, Paul Kennedy, BS, Bryan Hennessy, MD, Patrick Thornton, MB, FRCPath, John Quinn, MD PhD, Philip Murphy, MD

Blood (2018) 132 (Supplement 1): 5532.

https://doi.org/10.1182/blood-2018-99-114104

Published: 2018

Journal Articles

Younger Age at Diagnosis Is Associated with an Increased Risk of Venous Thromboembolism in Multiple Myeloma

Aisling Barrett, John Quinn, MD PhD, Siobhan Glavey, MD PhD, Jeremy Sargent, FRCPath, Michelle Lavin, MB, PhD FRCPath, Patrick Thornton, MB, FRCPath, James S O'Donnell, MD PhD, Philip Murphy, MD

Blood (2018) 132 (Supplement 1): 1223.

https://doi.org/10.1182/blood-2018-99-116148

Published: 2018

Journal Articles

Should Myelodysplastic Syndromes in Very Old Patients be More Actively Managed? Clinical Characteristics, Management and Outcomes for Patients 85 Years and Older

Laura McDonald, MB MRCPI, Peter McCarthy, MB BCh BAO, Mohammad Khan, MD, Patrick Hogan, MB BCh BAO, Eileen C. Kelleher, MD, Philip Murphy, MD, John Quinn, MD PhD, Ronan Desmond, MD, Johnny McHugh, MB, FRPATH, Melanie Strickland, BNS, Mary Cahill, MD, Su Wai Maung, MRCP, MBBS, Clodagh Keohane, MD, Desmond O'Neill, MD, Daniel Ryan, MD, Vitaliy Mykytiv, MD, Helen Enright, MD

Blood (2018) 132 (Supplement 1): 5515.

https://doi.org/10.1182/blood-2018-99-113290

Published: 2018

Journal Articles

A Phase II Multi-Center Study of Lenalidomide, Subcutaneous Bortezomib and Dexamethasone (RsqVD) in Newly Diagnosed Multiple Myeloma - Ctrial-IE (ICORG) 13-17 Study

Blood (2016) 128 (22): 2117.

https://doi.org/10.1182/blood.V128.22.2117.2117

Published: 2016

Journal Articles

Strong Correlation Between CTLA-4 and LEF1 Gene Expression Levels in CLL: Targeting of the Wnt/β-Catenin Pathway May Adversely Affect CTLA-4 Expression and Function

Philip T Murphy, MD, Gary Lynch, Stephen Bergin, John Quinn, MD PhD, Siobhan Glavey, MD, Philip W Murphy, Paul Kennedy

Blood (2016) 128 (22): 5571.

https://doi.org/10.1182/blood.V128.22.5571.5571

Published: 2016

NARROW

Ex Vivo Co-Culture of AML Blasts and Bone Marrow Mesenchymal Stromal Cells to Accurately Predict the Clinical Efficacy of Cytarabine-Daunorubicin Treatment

Cybord-Dara Is a Highly Effective Upfront Treatment for Newly Diagnosed Multiple Myeloma. Initial Efficacy Results of the 16-Bcni-001/Ctrial-IE (ICORG) 16-02 Study

Acitretin Reduces L-Selectin Expression and Tumour Cell Homing in Chronic Lymphocytic Leukaemia (CLL)

Younger Age at Diagnosis Is Associated with an Increased Risk of Venous Thromboembolism in Multiple Myeloma

Should Myelodysplastic Syndromes in Very Old Patients be More Actively Managed? Clinical Characteristics, Management and Outcomes for Patients 85 Years and Older

A Phase II Multi-Center Study of Lenalidomide, Subcutaneous Bortezomib and Dexamethasone (RsqVD) in Newly Diagnosed Multiple Myeloma - Ctrial-IE (ICORG) 13-17 Study

Strong Correlation Between CTLA-4 and LEF1 Gene Expression Levels in CLL: Targeting of the Wnt/β-Catenin Pathway May Adversely Affect CTLA-4 Expression and Function

Email alerts

ASH Publications

American Society of Hematology

Ex Vivo Co-Culture of AML Blasts and Bone Marrow Mesenchymal Stromal Cells to Accurately Predict the Clinical Efficacy of Cytarabine-Daunorubicin Treatment

Cybord-Dara Is a Highly Effective Upfront Treatment for Newly Diagnosed Multiple Myeloma. Initial Efficacy Results of the 16-Bcni-001/Ctrial-IE (ICORG) 16-02 Study

Acitretin Reduces L-Selectin Expression and Tumour Cell Homing in Chronic Lymphocytic Leukaemia (CLL)

Younger Age at Diagnosis Is Associated with an Increased Risk of Venous Thromboembolism in Multiple Myeloma

Should Myelodysplastic Syndromes in Very Old Patients be More Actively Managed? Clinical Characteristics, Management and Outcomes for Patients 85 Years and Older

A Phase II Multi-Center Study of Lenalidomide, Subcutaneous Bortezomib and Dexamethasone (RsqVD) in Newly Diagnosed Multiple Myeloma - Ctrial-IE (ICORG) 13-17 Study

Strong Correlation Between CTLA-4 and LEF1 Gene Expression Levels in CLL: Targeting of the Wnt/β-Catenin Pathway May Adversely Affect CTLA-4 Expression and Function

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only